| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMGN | Common Stock | Options Exercise | $3.92M | +25K | +86.4% | $156.35 | 54K | Feb 7, 2025 | Direct | F1 |
| transaction | AMGN | Common Stock | Sale | -$7.34M | -25K | -46.35% | $293.12 | 29K | Feb 7, 2025 | Direct | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMGN | Nqso (Right to Buy) | Options Exercise | $0 | -25K | -100% | $0.00 | 0 | Feb 7, 2025 | Common Stock | 25K | $156.35 | Direct |
| Id | Content |
|---|---|
| F1 | These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026. |
| F2 | The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. |
| F3 | These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |